Corrigendum to the Public Announcement (PA) made on Thursday, June 14, 2007

To the Shareholders of

KILITCH DRUGS (INDIA) LIMITED (KDIL)

Regd. Office: C-301/2, M.I.D.C. TTC Industrial Area, Pawane Village, Thane - 400 705

Tel. Nos: (022) 27630518, 27680913, 27619023 • Fax No: (022) 27680912.

Attention of Shareholders/beneficial owners is invited to the Public Announcement made on Thursday, June 14, 2007. The following changes may, please be noted and acted accordingly.

A. The Schedule of activity is revised as follows:

Activity	As per original PA	Revised
Public Announcement (PA)	Thursday, June 14, 2007	Thursday, June 14, 2007
Corrigendum to PA		Thursday, August 9, 2007
Specified date	Friday, July 06, 2007	Friday, July 06, 2007
Last date for a competitive bid	Thursday, July 05, 2007	Thursday, July 05, 2007
Letter of Offer to be posted to shareholders	Friday, July 27, 2007	Monday, August 13, 2007
Date of opening of the Offer	Thursday, August 02, 2007	Friday, August 17, 2007
Last date for withdrawing acceptance from the Offer	Tuesday, August 14, 2007	Friday, August 31, 2007
Date of closing of the Offer	Tuesday, August 21, 2007	Wednesday, September 5, 2007
Last date for revising the Offer price/number of Shares.	Wednesday, August 08, 2007	Monday, August 26, 2007
Last date of communicating rejection/acceptance and payment of consideration for applications accepted	Wednesday September 05, 2007	Thursday, September 20, 2007

B. PERSONS ACTING IN CONCERT WITH THE ACQUIRER (PACs)

M/s. Mukund P Mehta, Paresh P Mehta, Bhavin M Mehta and Prataprai K Mehta, promoters of the Target Company are Persons acting in Concert with the Acquirer (PACs).

Mr. Mukund P Mehta, aged 54 years, B Com, BGL residing at 143, Kalpataru Residency, 14th Floor, Near Cine Planet, Sion (West), Mumbai 400 022 has about 25 years experience in banking and other financial matters and has been involved in the manufacture and marketing of pharmaceutical formulations for the past 25 years. He is a promoter of the Target Company/its group Companies. He is Director of NBZ Pharma Ltd., Kilitch Drugs (India) Ltd. and Kilitch Pharma Company Ltd.

Mr. Paresh P Mehta, aged 47 years, B. Pharm residing 164, Kalpataru Residency, 14th Floor, Near Cine Planet, Sion (West), Mumbai 400 022 has about 25 years experience in pharmaceutical formulations business. He is a promoter of the Target Company/its group Companies. He is Director of NBZ Pharma Ltd., Kilitch Drugs (India) Ltd. and Kilitch Pharma Company Ltd.

Mr. Bhavin M Mehta, aged 31 years, B. Pharm, residing at 143, Kalpataru Residency, 14th Floor, Near Cine Planet, Sion (West), Mumbai 400 022, has about 10 years experience in pharmaceutical business. He is Managing Director of NBZ Pharma Ltd. He is a promoter of the Target Company/its group Companies. He is Director of Kilitch Pharma Company Ltd.

Mr. Prataprai K Mehta, aged 74 years, residing at 143, Kalpataru Residency, 14th Floor, Near Cine Planet, Sion (West), Mumbai 400 022 is a registered pharmacist and is having over 3 decades' experience in the pharmaceutical industry. He is a Director of NBZ Pharma Ltd., Kilitch Drugs (India) Ltd. and Kilitch Pharma Company Ltd.

As per Certificates (all dated 8th June 2007) issued by R S. Negi & Co., (Membership No. 107400) Chartered Accountant, B7, Ground Floor, Jadhav Nivas, S N Road, Mulund (West) Mumbai – 400 080 (Tel. No. (022) 30976131, E Mail ID: rbkanvin@gmail.com) the Net Worth of Mr. Mukund P Mehta as on 31.12.2006 is Rs. 223 Lacs, Net worth of Mr. Paresh P Mehta as on 31.12.2006 is Rs. 233 Lacs , the Net Worth of Mr. Bhavin M Mehta as on 31.12.2006 is Rs.72.80 Lacs and Net worth of Mr. Prataprai K Mehta as on 31.12.2006 is Rs. 252 Lacs.

The Acquirer and PACs have not entered into any agreement amongst themselves with regard to the Acquisition/Offer.

M/s. Mukund P Mehta, Paresh P Mehta, Bhavin M Mehta and Prataprai K Mehta, the PACs are on the Board of Directors of the Target Company and they shall recuse themselves and not participate in any matter(s) concerning or "relating" to the offer including any preparatory steps leading to the offer.

C. COMPLIANCE WITH CHAPTER II OF SEBI (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS 1997 : The filing of returns under Chapter II of SEBI (SAST) Regulations was made with a delay of 14 days for the year 1997 and 8 days for the year 1998, by the PACs as well as other promoter group Shareholders of the Target Company. The filings under Chapter II of the Regulations have been done within the stipulated time from 1999 till date. For non compliance with provisions of Chapter II for the years 1997 and 1998, by the promoters/promoter group Shareholders of the Target Company, SEBI may initiate suitable action, if any, at a later date.

D. LISTING OF SHARES ALLOTTED ON 12.06.2007: Final listing approval for the 61,45,000 Equity Shares allotted on preferential basis has been received from BSE on July 31, 2007.

E. RELATIONSHIP OF ACQUIRER WITH THE EXISTING PROMOTERS OF KDIL: NBZ Pharma Ltd., the main Acquirer, is promoted by the promoters of the Target Company and is a Promoter Group Company.

F. COMPLIANCE WITH REGULATION 21(2) & CLAUSE 40A OF THE LISTING AGREEMENT: Assuming full acceptance under this Offer, the post offer holding of the Public shall be 10.86 % of the voting Capital of KDIL. If consequent to the open offer, the public holding falls below the level required for continued listing, then the Acquirer/Promoter Group Shareholders/Target Company will comply with the relevant provisions of Clause 40A of the listing agreement in this regard, within the time limits stipulated therein. The Acquirer/PACs undertake and declare that they do not have any intention to delist the Equity Shares of Target Company, after the preferential allotment and Open Offer. They also undertake that they will comply with provisions of Clause 40A of the listing agreement, in this regard, within the time limits stipulated therein.

G. FURTHER ACQUISITION BY ACQUIRER/PACs/OTHER PROMOTER GROUP SHAREHOLDERS OF KDIL: The Acquirer/PACs, other promoter group Shareholders of KDIL have not acquired any Shares from the date of the Public Announcement till date.

H. SOURCE OF FUNDS/FUNDING ARRANGEMENT BY ACQUIRER: The details of source of the funds/funding arrangements to meet the funds requirement towards preferential allotment & Open Offer are as follows:

(Rs. In Lacs)

Source of funds	Amount
Term Loan from Shamrao Vithal Co Operative Bank Ltd.	1820
Term Loan from Shamrao Vithal Co operative Bank Ltd. (Against third party deposits)	810
Balance in Current Account No. 2079 with Shamrao Vithal Co operative Bank Ltd.	190
Corporate Loan from Kilitch Pharma Company Ltd., Gr. Company (Commercial transaction @ 11% interest per annum).	350
Unsecured Loans from Directors.	200
Internal cash Flows made available for the preferential allotment/open offer.	750
Total	**4120**

Issued by : Manager To The Offer

TRANSWARRANTY CAPITAL PVT LIMITED

SEBI Regn. No. 1NM 000010965

403, Regent Chambers, Nariman Point, Mumbai - 400 021

Tel. Nos.: (022) 66306090/66306091, 22047965, Fax No.: (022) 66306655

E Mail: premkumar@transwarranty.com

Contact Person: **Shri. G K Prem Kumar**

On Behalf of The Acquirer/PACs

NBZ PHARMA LIMITED (MAIN ACQUIRER)

Registered office: Ujagar Industrial Estate, Unit No: 37 to 41, Sub Plot, DWT Patil Marg, Deonar, Mumbai - 400 088. Tel. No.: (022) 67031655, (022) 67033322, Fax No.: (022) 67031658

E Mail Id: nbzjpp@mail.com

Persons Acting in Concert (PACs)

Mr. Mukund P Mehta, 143, Kalpataru Residency, Near Cine Planet, Sion (West), Mumbai 400 022, Tel. No. (022) 66661538Email Id: mukundmehta@kilitch.com

Mr. Paresh P Mehta, 164, Kalpataru Residency, Near Cine Planet, Sion (West), Mumbai 400 022, Tel. No. (022) 2401 4422, E Mail Id: pareshmehta@kilitch.com

Mr. Bhavin M Mehta, 143, Kalpataru Residency, Near Cine Planet, Sion (West), Mumbai 400 022, Tel. No. (022) 66661538 E Mail Id: bhavinmehta@kilitch.com

and

Mr. Prataprai K Mehta, 143, Kalpataru Residency, Near Cine Planet, Sion (West), Mumbai 400 022, Tel. No. (022) 66661538

Place: Mumbai

Date: August 9, 2007